Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect on Lipid Profile of Switching From Kivexa + Efavirenz to Atripla in HIV-1 Infected Adults With Raised Cholesterol
2007-003354-28Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Change from baseline in total fasting cholesterol at Week 12. Started Dec 2007; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-003354-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003354-28.